FINE FOODS & PHARMACEUTICALS (FF.MI) Stock Fundamental Analysis

BIT:FF • IT0005215329

11.6 EUR
+0.25 (+2.2%)
Last: Feb 24, 2026, 05:29 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

5

Taking everything into account, FF scores 5 out of 10 in our fundamental rating. FF was compared to 18 industry peers in the Life Sciences Tools & Services industry. FF has an average financial health and profitability rating. FF has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • In the past year FF was profitable.
  • FF had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: FF reported negative net income in multiple years.
  • FF had a positive operating cash flow in 4 of the past 5 years.
FF.MI Yearly Net Income VS EBIT VS OCF VS FCFFF.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M -60M -80M

1.2 Ratios

  • With a decent Return On Assets value of 6.89%, FF is doing good in the industry, outperforming 77.78% of the companies in the same industry.
  • With a decent Return On Equity value of 13.58%, FF is doing good in the industry, outperforming 72.22% of the companies in the same industry.
  • FF's Return On Invested Capital of 9.84% is fine compared to the rest of the industry. FF outperforms 72.22% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for FF is significantly below the industry average of 9.63%.
  • The 3 year average ROIC (3.16%) for FF is below the current ROIC(9.84%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 6.89%
ROE 13.58%
ROIC 9.84%
ROA(3y)-0.42%
ROA(5y)0.94%
ROE(3y)-1.24%
ROE(5y)0.96%
ROIC(3y)3.16%
ROIC(5y)3.16%
FF.MI Yearly ROA, ROE, ROICFF.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5

1.3 Margins

  • The Profit Margin of FF (5.07%) is worse than 66.67% of its industry peers.
  • With a Operating Margin value of 7.85%, FF is not doing good in the industry: 77.78% of the companies in the same industry are doing better.
  • FF's Operating Margin has improved in the last couple of years.
  • FF's Gross Margin of 34.77% is in line compared to the rest of the industry. FF outperforms 44.44% of its industry peers.
  • FF's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 7.85%
PM (TTM) 5.07%
GM 34.77%
OM growth 3Y24.97%
OM growth 5Y2.12%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.32%
GM growth 5Y2.27%
FF.MI Yearly Profit, Operating, Gross MarginsFF.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • FF has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • Compared to 1 year ago, FF has about the same amount of shares outstanding.
  • Compared to 5 years ago, FF has more shares outstanding
  • Compared to 1 year ago, FF has an improved debt to assets ratio.
FF.MI Yearly Shares OutstandingFF.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
FF.MI Yearly Total Debt VS Total AssetsFF.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • FF has an Altman-Z score of 3.24. This indicates that FF is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 3.24, FF is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
  • A Debt/Equity ratio of 0.44 indicates that FF is not too dependend on debt financing.
  • FF has a Debt to Equity ratio of 0.44. This is in the better half of the industry: FF outperforms 77.78% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Altman-Z 3.24
ROIC/WACC1.11
WACC8.87%
FF.MI Yearly LT Debt VS Equity VS FCFFF.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • FF has a Current Ratio of 1.67. This is a normal value and indicates that FF is financially healthy and should not expect problems in meeting its short term obligations.
  • FF's Current ratio of 1.67 is fine compared to the rest of the industry. FF outperforms 66.67% of its industry peers.
  • A Quick Ratio of 1.07 indicates that FF should not have too much problems paying its short term obligations.
  • FF's Quick ratio of 1.07 is fine compared to the rest of the industry. FF outperforms 61.11% of its industry peers.
Industry RankSector Rank
Current Ratio 1.67
Quick Ratio 1.07
FF.MI Yearly Current Assets VS Current LiabilitesFF.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • FF shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 147.03%, which is quite impressive.
  • FF shows a small growth in Revenue. In the last year, the Revenue has grown by 1.78%.
  • The Revenue has been growing by 8.83% on average over the past years. This is quite good.
EPS 1Y (TTM)147.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.62%
Revenue 1Y (TTM)1.78%
Revenue growth 3Y7.75%
Revenue growth 5Y8.83%
Sales Q2Q%12.18%

3.2 Future

  • FF is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.39% yearly.
  • FF is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.10% yearly.
EPS Next Y53.89%
EPS Next 2Y36.38%
EPS Next 3Y29.85%
EPS Next 5Y27.39%
Revenue Next Year4.41%
Revenue Next 2Y8.92%
Revenue Next 3Y9.15%
Revenue Next 5Y12.1%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
FF.MI Yearly Revenue VS EstimatesFF.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
FF.MI Yearly EPS VS EstimatesFF.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.2 -0.2 0.4 0.6 0.8

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • FF is valuated correctly with a Price/Earnings ratio of 13.03.
  • Based on the Price/Earnings ratio, FF is valued cheaper than 94.44% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of FF to the average of the S&P500 Index (26.98), we can say FF is valued rather cheaply.
  • The Price/Forward Earnings ratio is 16.52, which indicates a correct valuation of FF.
  • FF's Price/Forward Earnings ratio is rather cheap when compared to the industry. FF is cheaper than 83.33% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of FF to the average of the S&P500 Index (28.01), we can say FF is valued slightly cheaper.
Industry RankSector Rank
PE 13.03
Fwd PE 16.52
FF.MI Price Earnings VS Forward Price EarningsFF.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, FF is valued cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 6.76
FF.MI Per share dataFF.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • FF's earnings are expected to grow with 29.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.24
PEG (5Y)N/A
EPS Next 2Y36.38%
EPS Next 3Y29.85%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 1.27%, FF has a reasonable but not impressive dividend return.
  • Compared to an average industry Dividend Yield of 0.44, FF pays a better dividend. On top of this FF pays more dividend than 100.00% of the companies listed in the same industry.
  • Compared to the average S&P500 Dividend Yield of 1.81, FF is paying slightly less dividend.
Industry RankSector Rank
Dividend Yield 1.27%

5.2 History

  • The dividend of FF has a limited annual growth rate of 4.24%.
Dividend Growth(5Y)4.24%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • 18.40% of the earnings are spent on dividend by FF. This is a low number and sustainable payout ratio.
  • FF's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP18.4%
EPS Next 2Y36.38%
EPS Next 3Y29.85%
FF.MI Yearly Income VS Free CF VS DividendFF.MI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M
FF.MI Dividend Payout.FF.MI Dividend Payout, showing the Payout Ratio.FF.MI Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

FINE FOODS & PHARMACEUTICALS

BIT:FF (2/24/2026, 5:29:20 PM)

11.6

+0.25 (+2.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-06
Earnings (Next)03-11
Inst Owners12%
Inst Owner ChangeN/A
Ins Owners53.17%
Ins Owner ChangeN/A
Market Cap255.90M
Revenue(TTM)373.66M
Net Income(TTM)18.62M
Analysts86.67
Price Target12.7 (9.48%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.27%
Yearly Dividend0.12
Dividend Growth(5Y)4.24%
DP18.4%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.49%
PT rev (3m)1.49%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)13.48%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.13%
Revenue NY rev (3m)-2.2%
Valuation
Industry RankSector Rank
PE 13.03
Fwd PE 16.52
P/S 0.7
P/FCF N/A
P/OCF 6.94
P/B 1.87
P/tB 2.06
EV/EBITDA 6.76
EPS(TTM)0.89
EY7.67%
EPS(NY)0.7
Fwd EY6.05%
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)1.67
OCFY14.42%
SpS16.64
BVpS6.22
TBVpS5.62
PEG (NY)0.24
PEG (5Y)N/A
Graham Number11.16
Profitability
Industry RankSector Rank
ROA 6.89%
ROE 13.58%
ROCE 14.28%
ROIC 9.84%
ROICexc 11.04%
ROICexgc 11.92%
OM 7.85%
PM (TTM) 5.07%
GM 34.77%
FCFM N/A
ROA(3y)-0.42%
ROA(5y)0.94%
ROE(3y)-1.24%
ROE(5y)0.96%
ROIC(3y)3.16%
ROIC(5y)3.16%
ROICexc(3y)3.64%
ROICexc(5y)4.57%
ROICexgc(3y)4.02%
ROICexgc(5y)5.02%
ROCE(3y)4.59%
ROCE(5y)4.62%
ROICexgc growth 3Y13.05%
ROICexgc growth 5Y-1.19%
ROICexc growth 3Y17.44%
ROICexc growth 5Y-2.63%
OM growth 3Y24.97%
OM growth 5Y2.12%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.32%
GM growth 5Y2.27%
F-Score7
Asset Turnover1.36
Health
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Debt/EBITDA 1.35
Cap/Depr 262.56%
Cap/Sales 11.33%
Interest Coverage 250
Cash Conversion 82.61%
Profit Quality N/A
Current Ratio 1.67
Quick Ratio 1.07
Altman-Z 3.24
F-Score7
WACC8.87%
ROIC/WACC1.11
Cap/Depr(3y)145.26%
Cap/Depr(5y)138.08%
Cap/Sales(3y)9.82%
Cap/Sales(5y)9.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)147.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.62%
EPS Next Y53.89%
EPS Next 2Y36.38%
EPS Next 3Y29.85%
EPS Next 5Y27.39%
Revenue 1Y (TTM)1.78%
Revenue growth 3Y7.75%
Revenue growth 5Y8.83%
Sales Q2Q%12.18%
Revenue Next Year4.41%
Revenue Next 2Y8.92%
Revenue Next 3Y9.15%
Revenue Next 5Y12.1%
EBIT growth 1Y70.93%
EBIT growth 3Y34.65%
EBIT growth 5Y11.14%
EBIT Next Year142.69%
EBIT Next 3Y46.91%
EBIT Next 5Y31.96%
FCF growth 1Y57.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y568.5%
OCF growth 3YN/A
OCF growth 5Y19.07%

FINE FOODS & PHARMACEUTICALS / FF.MI FAQ

What is the fundamental rating for FF stock?

ChartMill assigns a fundamental rating of 5 / 10 to FF.MI.


Can you provide the valuation status for FINE FOODS & PHARMACEUTICALS?

ChartMill assigns a valuation rating of 6 / 10 to FINE FOODS & PHARMACEUTICALS (FF.MI). This can be considered as Fairly Valued.


Can you provide the profitability details for FINE FOODS & PHARMACEUTICALS?

FINE FOODS & PHARMACEUTICALS (FF.MI) has a profitability rating of 5 / 10.


Can you provide the financial health for FF stock?

The financial health rating of FINE FOODS & PHARMACEUTICALS (FF.MI) is 5 / 10.


Can you provide the expected EPS growth for FF stock?

The Earnings per Share (EPS) of FINE FOODS & PHARMACEUTICALS (FF.MI) is expected to grow by 53.89% in the next year.